Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer

Trial statusCompleted
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexFemale
Age18+
SponsorUniversity of Chicago

About this trial

This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer. Doctors leading the study will also determine the safest and most tolerable dose of shortened radiation (hypofractionation) used to treat women in this study. Because this study will shorten the radiation course typically used to treat endometrial cancer, each daily treatment given to women in this study will be slightly higher than normal to ensure that the total radiation dose they receive is still effective and similar to the radiation dose they would receive if they were not participating in this study (standard treatment).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of primary cervical cancer or uterine cancer of any histology

Age ≥ 18 years.

Non-metastatic disease according to the International Federation of Gynecology and Obstetrics (FIGO).

Must have been treated with definitive intent, including standard-of-care hysterectomy, without any gross residual disease post-operatively. Nodal dissection is not required, but if it is not performed, then diagnostic imaging to confirm absence of gross pelvic or para-aortic disease should be obtained pre- or post-operatively.

Disqualifiers

Distant metastases as determined clinically or radiographically based upon standard-of-care work-up for endometrial cancer.

Concurrent (or other) chemotherapy occurring at the time of study.

Gross residual disease (cancer cells that remain after attempts to remove the cancer have been made) post-operatively and/or at the time of radiation based upon pre-op or post-op imaging, intra-operative findings, and gynecologic oncologists' judgment.

History of small bowel obstruction, inflammatory bowel disease, irritable bowel syndrome, connective tissue disorder requiring ongoing active medical management, or prior radiation therapy directed to the pelvis.

Trial design

Design model

Sequential

Treatments tested in this trial

  • Hypofractionated Radiation

    Radiation

    Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given less often. Hypofractionated radiation therapy is given over a shorter period of time (fewer days or weeks) than standard radiation therapy.

  • Clinical Follow-Up and Assessments

    Other intervention

    At each visit, the subject will be evaluated for any signs of their endometrial cancer or symptoms returning (clinical disease recurrence) and any negative side effects associated with their prior radiation treatment. Study participants will also be asked to fill out a survey regarding bowel/urinary habits and quality of life questionnaires (known as the "EPIC questionnaire") during these visits. The data collected during these clinical follow up visits will be used to determine how effective hypofractionated/shortened whole radiation therapy is for treating endometrial cancer.

Treatment groups

35 Participants
are divided into 2 treatment groups
Group A: Hypofractionated Radiation Treatment (Dose-Finding Arm)Experimental treatment 1 intervention
Group B: Expansion Cohort (Efficacy Arm)Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

The Maximum Tolerated Dose of Hypofractionated Whole Pelvic Radiation Treatment (Phase 1)

The maximum tolerated dose-per-fraction regimen of whole pelvic radiation therapy that will be administered during uterine cancer treatment.

Time frame
3-5 weeks
2

Change in patient-reported acute gastrointestinal side effects after completion of hypofractionated radiation (Phase 2)

Change in quality-of-life experience on the bowel and urinary domains

Time frame
3-5 weeks (end of treament)

Secondary outcomes

1

Change in patient-reported acute urinary side effects

Determined using frequency of reported events of urinary frequency, urinary incontinence, and urinary urgency on the Patient Reported Outcomes (PRO-CTCAE)

Time frame
1 month post radiation
2

Change in gastrointestinal toxicity over time

Determined using frequency of reported events of diarrhea and proctitis on the Patient Reported Outcomes (PRO-CTCAE)

Time frame
1 month post radiation
3

Overall quality of life after treatment

Total quality of life score from the Functional Assessment of Cancer Therapy (FACT)-General questionnaire will be calculated. A higher score indicates better quality of life.

Time frame
2 years post treatment
4

Financial Distress of Treatment

Change in reported financial distress in patients as reported on the Functional Assessment of Chronic Illness Therapy- COST (FACIT-COST) questionnaire. Higher scores on scale of 0-5 indicates better financial wellbeing.

Time frame
End of treatment

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: